Nitric oxide attenuates the expression of transforming growth factor-beta(3) mRNA in rat cardiac fibroblasts via destabilization

Hypertension. 2001 Aug;38(2):261-6. doi: 10.1161/01.hyp.38.2.261.

Abstract

Transforming growth factor-beta (TGF-beta) has been implicated in the development of interstitial fibrosis in cardiac hypertrophy. NO has been regarded as a potent inhibitor of cardiac fibroblast growth, albeit the modulation of cellular events associated with interstitial fibrosis remains undefined. In this regard, the regulation of TGF-beta mRNA expression by the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) was examined in neonatal rat cardiac fibroblasts. SNAP treatment for 4 hours decreased TGF-beta(3) mRNA levels, an effect mimicked by 8-bromo-cGMP. TGF-beta(3) mRNA, however, had returned to levels observed in the untreated cells after a 24-hour exposure to SNAP, whereas a decreased expression persisted with 8-bromo-cGMP. In contrast to TGF-beta(3), TGF-beta(1) mRNA levels were modestly increased in response to cGMP-generating molecules. The treatment with actinomycin D for at least 8 hours did not appreciably alter TGF-beta(3) mRNA levels. By contrast, SNAP treatment caused a rapid decrease of TGF-beta(3) mRNA with a half-life of 3.3+/-0.2 hours, thereby supporting a mechanism of destabilization. The pretreatment with SNAP inhibited angiotensin II-stimulated protein synthesis and the concomitant expression of TGF-beta(3) mRNA. These data reveal a disparate pattern of TGF-beta(1) and TGF-beta(3) mRNA regulation by NO and highlight a novel mechanism of destabilization contributing to the decreased expression of TGF-beta(3) mRNA. The modulation of both basal and angiotensin II-stimulated TGF-beta(3) mRNA expression provides a mechanism by which NO may influence the progression of interstitial fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology
  • Animals
  • Animals, Newborn
  • Cells, Cultured
  • Cyclic GMP / analogs & derivatives
  • Cyclic GMP / biosynthesis
  • Cyclic GMP / pharmacology
  • Drug Antagonism
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism*
  • Kinetics
  • Myocardium / cytology*
  • Nitric Oxide / physiology*
  • Penicillamine / administration & dosage
  • Penicillamine / analogs & derivatives
  • Penicillamine / pharmacology
  • RNA Stability*
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Sprague-Dawley
  • S-Nitroso-N-Acetylpenicillamine
  • Transcription, Genetic
  • Transforming Growth Factor beta / biosynthesis
  • Transforming Growth Factor beta / genetics*
  • Transforming Growth Factor beta1
  • Transforming Growth Factor beta3

Substances

  • RNA, Messenger
  • Tgfb1 protein, rat
  • Tgfb3 protein, rat
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
  • Transforming Growth Factor beta3
  • Angiotensin II
  • 8-bromocyclic GMP
  • Nitric Oxide
  • S-Nitroso-N-Acetylpenicillamine
  • Penicillamine
  • Cyclic GMP